1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

Slides:

Advertisements

Similar presentations

Pramlintide Acetate Safety Review Dragos Roman MD Center for Drug Evaluation and Research.

Advertisements

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

HIV Drug Development in Neonates - What Now? Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products FDA.

1 One Year Post-Exclusivity Adverse Event Review for Tamiflu® (oseltamivir) Pediatric Advisory Committee Meeting November 18, 2005 Melissa M. Truffa, R.Ph.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

1 One Year Post-Exclusivity Adverse Event Review: Sirolimus Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Afrezza® – inhaled human insulin

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Orlistat Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

1 One Year Post-Exclusivity Adverse Event Review: Oxcarbazepine Pediatric Advisory Committee Meeting November 16, 2006 Felicia L. Collins, MD, MPH, FAAP.

Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

1. SH.ARBABI, M.D Endocrinology Center 18-OCT-2007.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee Meeting September 15, 2004

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

1 One Year Post-Exclusivity Adverse Event Review: Linezolid Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Toujeo® and it’s Place in Therapy

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

VIOXX ™ Gastrointestinal Outcome Research (VIGOR) Arthritis Advisory Committee Meeting February 8, 2001 Lourdes Villalba, M.D. DAAODP, CDER, FDA.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

1 One Year Post-Exclusivity Adverse Event Review: Norgestimate/ethinyl estradiol Pediatric Advisory Committee Meeting June 29, 2005 Hari Cheryl Sachs,

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post Exclusivity Adverse Event Review: Sibutramine Pediatric Advisory Committee Meeting March 22, 2006 Hari Cheryl Sachs, MD, FAAP Medical Officer.

1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,

Tresiba- insulin degludec

Multidisciplinary Diabetes Team Activities in a 196 Bed Community Hospital Robin Southwood, Pharm.D, CDE and Beth Melvin, RD, MS, CDE.

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Diabetes Update: Michael Gottschalk, M.D, Ph.D.

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.

Diabetes Mellitus Part 2 Kathy Martin DNP, RN, CNE.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Faster-Acting Insulins

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

Presentation transcript:

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical Officer Pediatric and Maternal Health Staff Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Drug: NovoLog ® (insulin aspart recombinant) Therapeutic Category: human insulin analog Sponsor: Novo Nordisk Inc Original Market Approval: June 7, 2000 Pediatric Exclusivity Granted: May 24, 2005 Mechanism of action: regulation of glucose metabolism –Binds to insulin receptors on muscle and fat –Facilitates cellular uptake of glucose –Inhibits output of glucose from liver

3 Background Drug Information Indication: treatment of patients with diabetes mellitus, for the control of hyperglycemia –Normally with regimen of intermediate or long-acting insulin –May be infused via external insulin pumps –May be used intravenously under medical supervision Dosage: –Individualized, immediately prior to a meal

4 Drug Use Trends (Outpatient Settings): Insulin Aspart Recombinant Dispensed prescriptions for NovoLog have been increasing (June 2004 to May 2006) 1 –Total NovoLog ® and NovoLog ® Mix 70/30 prescriptions increased by estimated 29% (~ 2.4 to 3.4 million) 1 –Relative increase in pediatric patient count: 22% (~47,000 to 57,000) 2 Pediatric patients accounted for ~13% of prescriptions 2 Majority of pediatric NovoLog ® prescriptions to patients ages years 1 1 Verispan LLC, Vector One National, Jun 2003 to May 2006, Data extracted Jul Verispan LLC, Vector One National: Total Patient Tracker, Data Extracted 7/2006 Excludes NovoLog® Mix 70/30

5 Pediatric Exclusivity Labeling changes: Insulin Aspart Recombinant Indicated for use in pediatric patients Pk and clinical studies described, including those in children ages 2 to 6 years Glycemic control and adverse events, particularly hypoglycemia comparable to regular insulin

6 Adverse Event Reports since Market Approval (June 2000): Insulin Aspart All reports (US)Serious (US)Death (US) All Ages*1338 (1056)616 (341)36 (8) Adults (> 17)1051 (828)491 (275)30 (8) Pediatrics (0-16)154 (117)72 (35)5 (0) *may include duplicates and unknown ages Serious outcomes per regulatory definition include death, hospitalization, life-threatening, disability, congenital anomaly, requiring intervention, and other

7 Fatal Serious AE since approval: Insulin Aspart (n= 4, unduplicated) Infants born to participants in post-marketing clinical trial in pregnant women with diabetes: 4 month old female with truncus arteriosus communis 4 day old male with hypoxic ischemic encephalopathy and seizures Direct exposures 14 year old male with type I DM and remote history of asthma found dead in bed, treated for 4-5 months with insulin detemir and aspart; post mortem: “consistent with acute asthma attack, although patient had not had attack in 8 years.” 9 year old male with type 2 DM on insulin glargine for 6 months and aspart for unknown period, died, “possible alcohol overdose” Underlined events are not specifically labeled

8 Adverse Event Reports One Year Post Exclusivity Period: Insulin Aspart Raw counts*All reports (US)Serious (US)Death (US) All ages284 (169)249 (135)15 (1) Adults (> 17)230 (135)202 (108)12 (1) Pediatrics (0-16)28 (18)24 (14)3 (0) * may include duplicates and unknown ages

9 Adverse Event Reports during One-Year Post Exclusivity Period: Unlabeled Serious Non-fatal cases: Insulin Aspart. In utero exposure (n =4) –Newborn with neonatal hypoglycemia and ankyloglossia, first trimester exposure insulin lispro, regular insulin, NovoLog® –37 week with urinary retention, neonatal asphyxia, and hypoxic-ischemic lesion of the central nervous system, first trimester exposure multiple drugs –Neonate with dysmorphy of the right frontal lobe, increased frontal subarachnoid space, and assymetry of lateral ventricle –32 week preterm with neonatal hypoglycemia (blood glucose 24 mg/dl) Underlined events are unlabeled

10 Summary: Insulin Aspart Labeling updated after exclusivity studies –Treatment of type I DM > 2 years –Most frequent AE is hypoglycemia During post exclusivity period –Although AEs related to in utero exposure observed, no pattern –No new pediatric AEs identified This completes the one-year post-exclusivity AE reporting as mandated by BPCA. The FDA recommends routine monitoring of insulin aspart recombinant for AEs in all populations. Does the Advisory Committee concur?

11 Acknowledgements OSE Andrea Feight Lanh Green Solomon Iyasu Rosemary Johann-Liang David Moeny Joslyn Swann DMEP David Orloff Joanna Zawadzki PMHS Lisa Mathis Kristin Phucas Jean Temeck